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Background: P-glycoprotein is a blood–brain barrier efflux transporter involved in the clearance of amyloid-beta
from the brain and, as such, might be involved in the pathogenesis of Alzheimer's disease. P-glycoprotein is
encoded by the highly polymorphic ABCB1 gene. Single-nucleotide polymorphisms in the ABCB1 gene have been
associated with altered P-glycoprotein expression and function. P-glycoprotein function at the blood–brain barrier
can be quantified in vivo using the P-glycoprotein substrate tracer (R)-[11C]verapamil and positron emission
tomography (PET). The purpose of this study was to assess the effects of C1236T, G2677T/A and C3435T
single-nucleotide polymorphisms in ABCB1 on blood–brain barrier P-glycoprotein function in healthy subjects and
patients with Alzheimer's disease.
Methods: Thirty-two healthy subjects and seventeen patients with Alzheimer's disease underwent 60-min dynamic
(R)-[11C]verapamil PET scans. The binding potential of (R)-[11C]verapamil was assessed using a previously validated
constrained two-tissue plasma input compartment model and used as outcome measure. DNA was isolated from
frozen blood samples and C1236T, G2677T/A and C3435T single-nucleotide polymorphisms were amplified by
polymerase chain reaction.
Results: In healthy controls, binding potential did not differ between subjects without and with one or more
T present in C1236T, G2677T and C3435T. In contrast, patients with Alzheimer's disease with one or more T in
C1236T, G2677T and C3435T had significantly higher binding potential values than patients without a T. In addition,
there was a relationship between binding potential and T dose in C1236T and G2677T.
Conclusions: In Alzheimer's disease patients, C1236T, G2677T/A and C3435T single-nucleotide polymorphisms may
be related to changes in P-glycoprotein function at the blood–brain barrier. As such, genetic variations in ABCB1
might contribute to the progression of amyloid-beta deposition in the brain.
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P-glycoprotein (Pgp) is a 170 kDa membrane-bound
efflux transporter located in several organs throughout
the body with an excretory and/or barrier function,
such as the liver, kidneys, intestine, placenta, testes and
the blood–brain barrier (BBB) [1]. At the BBB, Pgp
is highly expressed and has an important function in* Correspondence: d.vanassema@vumc.nl
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reproduction in any medium, provided the origthe transport of a wide variety of endogenous and
exogenous substances out of the brain into the blood-
stream [2]. Pgp has been shown to play a role in
amyloid-beta clearance from the brain and, as such, has
been hypothesized to be involved in the pathogenesis of
Alzheimer's disease (AD) [3]. Recently, BBB Pgp dys-
function in AD patients was shown using the Pgp sub-
strate tracer (R)-[11C]verapamil and positron emission
tomography (PET) [4].
Pgp is encoded in the ABCB1 gene (formerly known
as the multidrug resistance (MDR1) gene), which spansis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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on chromosome 7q21 [5]. The ABCB1 gene is highly
polymorphic, and to date, over a hundred single-
nucleotide polymorphisms (SNPs) of this gene have been
discovered [5]. The majority of SNPs are either intronic
or non-coding. Only a minority of variants in the coding
region lead to a change in amino acids [5,6].
In Caucasian subjects, high SNP frequencies in ABCB1
were observed for 3435T in exon 26 (54%) and 2677G in
exon 21 (56%). High SNP frequencies were also found
for 2677T (42%) and 1236T in exon 12 (46%) [5,7]. Of
the 15 most frequently occuring SNPs, the synonymous
variant (no amino acid exchange) C1236T (rs1128503),
the non-synonymous variant G2677T/A (amino acid
exchanges Ala893Ser or Ala893Thr) (rs2032582) and the
synonymous variant C3435T (rs1045642) are most
widely studied regarding their consequences for Pgp
function and/or expression [5,6].
Altered transport function of Pgp was observed for the
C3435T SNP, as the 3435T allele was associated with
decreased Pgp expression in the duodenum, and
increased oral bioavailability of the Pgp substrate digoxin
[8]. On the other hand, others could not replicate these
findings, and even opposite effects of this SNP have been
shown [9,10]. Whilst in vitro studies did not find effects
of the G2677T/A SNP [11,12], another study showed an
association with decreased Pgp expression in the human
placenta [13].
Highly significant linkage disequilibrium was shown
among exons 12 C1236T, 21 G2677T and 26 C3435T,
which could account for most of the haplotypes (combi-
nations of SNPs) seen in ABCB1 [13-15]. To date, two
studies have assessed the effects of ABCB1 haplotypes
on BBB Pgp function using PET and [11C]verapamil. In
these studies, healthy subjects with the homozygous
TTT haplotype (1236T, 2677T and 3435T) did not differ
in brain distribution of [11C]verapamil from subjects
with the homozygous CGC haplotype (1236C, 2677G
and 3435C) [16,17].
As Pgp is involved in amyloid-beta clearance at the
BBB, genetic variations in ABCB1 might be related to
an inherited change in the risk of developing AD [3].
Analysis of ABCB1 SNPs in combination with in vivo
measurement of BBB Pgp function in AD is needed to
further evaluate this hypothesis. Therefore, the purpose
of this study was to assess the effects of C1236T,
G2677T/A and C3435T SNPs on BBB Pgp function in
both AD patients and healthy subjects.
Methods
Participants
Thirty-two healthy controls and seventeen AD patients
were included in this study. All participants underwent
a standardized clinical assessment, including medicalhistory, family history, use of medication and drugs of
abuse and physical and neurological examinations. All
subjects had normal scores on screening laboratory
tests. Medication at the time of scanning was not
allowed, except for medication known not to interfere
with Pgp function [18,19]. Controls fulfilled research cri-
teria of never having been mentally ill, and they had nor-
mal brain magnetic resonance imaging (MRI) scans and
Mini-Mental State Examination (MMSE) scores within
the normal range (MMSE > 26) [20]. For AD patients, a
clinical diagnosis of probable AD was established by
consensus in a multidisciplinary meeting according to
the criteria proposed by the National Institute of Neuro-
logical and Communicative Disorders and Stroke and
the Alzheimer's Disease and Related Disorders Associa-
tion [21]. Increased cortical accumulation of [11C]PIB
PET was required to confirm presence of amyloid
pathology in the brain [22]. Written informed consent
was obtained from all participants after a complete writ-
ten and verbal description of the study, and the study
was approved by the Medical Ethics Review Committee
of the VU University Medical Center.MRI
Participants underwent structural MRI scans using
either a 1.0-T Magnetom Impact scanner (Siemens
Medical Solutions, Erlangen, Germany) or a 1.5-T
Sonata scanner (Siemens Medical Solutions). The scan
protocol included an identical coronal T1-weighted 3-D
magnetization-prepared rapid acquisition gradient-echo
sequence, which was used for co-registration and
region-of-interest (ROI) definition.PET
All PET scans were acquired using an ECAT EXACT
HR+ scanner (Siemens/CTI, Knoxville, TN, USA) [23].
Participants received an indwelling radial artery canula
for arterial sampling and a venous canula for tracer
injection. After a 10-min transmission scan in 2D
acquisition mode, which was used to correct the subse-
quent emission scan for photon attenuation, a dynamic
3D emission scan was started simultaneously with the
injection of 369 ± 19 MBq (R)-[11C]verapamil, adminis-
tered using an infusion pump (Med-Rad, Beek, The
Netherlands). The 60-min emission scan consisted of
20 frames with progressive increase in frame duration.
Arterial blood was withdrawn continuously using an
online sampling device (Veenstra Instruments, Joure,
The Netherlands) [24]. At set times, continuous sam-
pling was interrupted briefly, and manual samples were
taken. A detailed description of scanning and sampling
procedures has been reported previously [4].
Table 1 Prevalence of different SNPs in healthy controls
and Alzheimer's disease patients
HC AD
C1236T CC 11 (34%) 3 (18%)
CT 11 (34%) 8 (47%)
TT 10 (31%) 6 (35%)
G2677T/A GG 10 (31%) 3 (18%)
TG 10 (31%) 8 (47%)
TT 10 (31%) 6 (35%)
C3435T CC 8 (25%) 2 (12%)
CT 15 (47%) 9 (53%)
TT 9 (28%) 6 (35%)
SNPs, single nucleotide polymorphisms; HC, healthy control group; AD,
Alzheimer's disease patient group.
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All PET sinograms were corrected for dead time, tissue
attenuation, decay, scatter and randoms. PET scans were
reconstructed using a standard filtered back projection
algorithm, applying a Hanning filter with a cut-off at
0.5 times the Nyquist frequency. A zoom factor of 2 and
a matrix size of 256 × 256 × 63 were used, resulting in a
voxel size of 1.2 × 1.2 × 2.4 mm and a spatial resolution
of approximately 6.5 mm full-width at half-maximum at
the centre of the field of view. Co-registration of struc-
tural T1 MR images with corresponding PET images
and segmentation of the co-registered MRI into the
grey matter, white matter and cerebrospinal fluid was
performed using statistical parametrical mapping (SPM,
version SPM2, www.fil.ion.ucl.ac.uk/spm, Institute of
Neurology, London, UK). ROIs were defined on the
basis of the segmented MRI and a probabilistic template
as implemented in PVElab [25]. ROIs were mapped onto
dynamic PET images, generating regional time-activity
curves. A global cortical region was defined consisting of
the volume-weighted average of the frontal, parietal,
temporal and occipital cortices and posterior and ante-
rior cingulate regions [4].
The original on-line blood curve was calibrated using
whole blood radioactivity concentrations derived from
the manual samples. The calibrated whole blood curve
was multiplied with a single-exponential fit to the
plasma-to-whole blood ratios of these samples, thereby
generating a total plasma curve. Finally, the metabolite-
corrected plasma input function was obtained by multi-
plying this total plasma curve with a sigmoid fit to one
minus the polar metabolite fraction [26,27].
Kinetic analyses were performed using software devel-
oped within Matlab 7.04 (The Mathworks, Natick, MA,
USA). (R)-[11C]verapamil data were analysed using a
previously validated constrained two-tissue compart-
ment plasma input model [28]. The non-displaceable
binding potential (BPND) was used as outcome measure.
Again, data analysis and kinetic modeling procedures
have been described in detail elsewhere [4].
DNA isolation and molecular analysis
The DNAs of 49 samples were isolated from 4 mL of
frozen blood samples using the Gentra Puragene Blood
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer's protocol. C1236T, G2677T/A and C3435T
polymorphisms were amplified by polymerase chain
reaction (PCR) using the following conditions: 12.5 ng
DNA; 1X PCR buffer; 0.2 μM of each dNTP; 0.7 μM
of each primer (C1236T F: 50-TTGAATGAAGAGT
TTCTGATGTTTTC-30, R: 50-CCTGTCCATCAACACT
GACC-30; G2677T/A F: 50-TTCTCTAATTTGTTTTG
TTTTGCAG-30, R: 50-AAAAGATTGCTTTGAGGAATGG-30; C3435T F: 50-GTGTGCTGGTCCTGAAGT
TG-30, R: 50-AGAGAGGCTGCCACATGC-30); 2 mM
MgCl2 and 0.03 u of Fast Taq polymerase (Roche, Basel,
Switzerland) 5-min initial denaturation at 95°C; 35× cycles
at 95°C denaturation for 30 s, 58°C annealing for 30 s and
72°C extension for 30 s, and a final extension at 72°C for
10 min. The resulting PCR products were purified by
SAP/Exo treatment (GE Healthcare, Little Chalfont, UK),
and both strands were sequenced using the Big Dye
Terminators v3.0 Sequencing Kit (Life Technologies,
Carlsbad, CA, USA) on ABI 3730 (Life Technologies,
Carlsbad, CA, USA) and analysed using Seqscape software
(Life Technologies, Carlsbad, CA, USA).
Statistical analysis
Statistical analyses were performed using SPSS 15.0
(SPSS Institute, Chicago, Ill, USA). Values are presented
as mean ± standard deviation (SD). Differences in BPND
between groups were assessed using non-parametric
Mann–Whitney U tests. A general linear model (GLM)
with T dose as the continuous measure was used to
assess the effects of T dose on BPND. The threshold for
significance was set at p < 0.05.
Results
Thirty-two healthy controls (14 females) with a mean age
of 47 ± 17 years and seventeen AD patients (5 females) with
a mean age of 64 ± 7 years were included in the study.
The prevalence of C1236T, G2677T and C3435T SNPs
in both healthy controls and AD patients is listed in
Table 1. Of the subjects who were homozygous for the
1236T SNP, 94% were also homozygous for the 2677T
SNP. In addition, 73% of the subjects who were homo-
zygous for the 3435T SNP were also homozygous for the
2677T SNP.
First, healthy controls and AD patients were dichoto-
mized into a group with no T present and a group with
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SNPs separately. For each SNP, (R)-[11C]verapamil BPND
was compared between these two groups. In healthy
controls, no differences in BPND between these groups
were found (Table 2). In AD patients however, signifi-
cantly higher BPND values were found in patients with
one or more T present in C1236T, G2677T and C3435T
SNPs than in those with no T present (Table 2).
In addition, the effect of T dose (0 T, 1 T or 2
T present) in C1236T, G2677T and C3435T SNPs
was assessed. In healthy controls, no effect of T dose on
(R)-[11C]verapamil BPND was found (Figure 1). Again, in
AD patients, an effect of T dose in C1236T and G2677T
SNPs on (R)-[11C]verapamil BPND was found (p < 0.05),
whilst in C3435T SNP, a trend was observed (p = 0.14),
all with higher BPND values for higher T dose (Figure 1).
Discussion
In healthy controls, no effects of SNPs in C1236T,
G2677T/A and C3435T on Pgp function at the BBB
were found in vivo. In contrast, in AD patients, both the
presence of T as well as T dose in C1236T, G2677T/A
and C3435T were related with increased BPND of (R)-
[11C]verapamil, suggesting decreased Pgp function at
the BBB.
Two previous PET studies, assessing effects of ABCB1
haplotypes on BBB Pgp function in healthy subjects, also
did not find differences in the brain uptake of [11C]vera-
pamil [16,17]. Before the present study, however,
no studies have been performed assessing effects of
genetic variations in ABCB1 on in vivo BBB Pgp func-
tion in AD patients.
The present study showed a selective effect of the
C1236T, G2677T and C3435T SNPs in ABCB1 on BBB
Pgp function in AD patients. As, using (R)-[11C]verapa-
mil PET, BBB Pgp dysfunction in AD patients has been
shown previously [4], the present data suggest that
genetic variations in the ABCB1 gene might affect Pgp
function or expression at the BBB, only when Pgp func-
tion is already compromised. Therefore, in AD patients,
genetic variations in ABCB1 could contribute to diseaseTable 2 Global (R)-[11C]verapamil BPND in healthy
controls and Alzheimer's disease patients after
dichotomization on presence of T
Number HC Number AD
C1236 no T 11 1.76 ± 0.45 3 1.74 ± 0.33
T present 21 1.78 ± 0.43 14 2.16 ± 0.29*
G2677T/A no T 11 1.76 ± 0.45 3 1.74 ± 0.33
T present 21 1.78 ± 0.43 14 2.16 ± 0.29*
C3435T no T 8 1.73 ± 0.49 2 1.56 ± 0.15
T present 24 1.79 ± 0.42 15 2.15 ± 0.28*
HC, healthy control group; AD, Alzheimer's disease patient group; * = p < 0.05.progression as an additional decrease in BBB Pgp func-
tion may lead to an increased rate of accumulation of
toxic substances, such as amyloid-beta, in the brain.
Alternatively, it is also possible that certain genetic varia-
tions in ABCB1 have a more primary role in developing
neurodegenerative diseases such as AD or Parkinson's dis-
ease (PD). For example, in subjects that were exposed to
organochlorine insecticides, polymorphisms in ABCB1,
associated with decreased ability to clear xenobiotics from
the brain, increased the risk of PD [29].
In the present study, the prevalences of different var-
iants in C1236T, G2677T and C3435T SNPs in ABCB1
were comparable between AD patients and healthy con-
trols. A previous pilot study in relatively small groups of
demented patients and healthy subjects showed no sig-
nificant differences in the prevalence of C1236T,
G2677T/A and C3435T [30]. Nevertheless, a large
population-based study would be needed to assess possi-
ble differences in prevalence of genetic variations in
ABCB1 between healthy controls and AD patients. Only
such a larger study could provide insight into the role
of ABCB1 SNPs and haplotypes as a possible risk factor
for developing AD. In a subset of such a study, BBB
Pgp function should be measured to further evaluate the
relationship between ABCB1 SNPs and haplotypes,
and BBB Pgp function in both healthy controls and
AD patients.
The prevalences of different variants in C1236T,
G2677T/A and C3435T in this study were comparable
to those reported previously [5,7]. In addition, linkage
disequilibrium between the three SNPs, observed in the
present study, has also been described before [13-15]. It
could very well be that the effects of the different SNPs
in ABCB1 that we have found in AD patients are physio-
logically effectuated through the linkage disequilibrium
via the G2677T SNP, which is a non-synonymous var-
iant, thus changing amino acid sequence, while the
mutations in C1236T and C3435T are synonymous [5,6].
At present, measuring Pgp function at the BBB in vivo
can only be performed using (R)-[11C]verapamil PET
with arterial blood sampling. Consequently, group sizes
in the present study are limited, and findings need to be
replicated in larger trials, preferably using methods with-
out arterial sampling. Another limitation of the present
study is the fact that it is not possible to differentiate
between decreased Pgp function due to decreased BBB
Pgp transporter expression or decreased Pgp transport
functionality with intact transporter expression. This can
only be addressed when a PET tracer of Pgp expression
becomes available.
Conclusions
Single-nucleotide polymorphisms in C1236T, G2677T
and C3435T are related to changes in BBB Pgp function
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Figure 1 Binding potential (BPND) of (R)-[
11C]verapamil. Global
BPND in healthy controls (HC, squares) and Alzheimer's disease
patients (AD, triangles) as a function of T dose in (A) C1236T, (B)
G2677T and (C) C3435T is shown. Mean BPND values and SD are
given. (A) C1236T: In HC, BPND values for 0 T, 1 T and 2 T were 1.76
± 0.45, 1.77 ± 0.45 and 1.79 ± 0.44, and in AD, the values were 1.74
± 0.33, 2.11 ± 0.37 and 2.22 ± 0.13, respectively. (B) G2677T: In HC,
BPND values for 0 T, 1 T and 2 T were 1.76 ± 0.45, 1.76 ± 0.44 and
1.81 ± 0.44, and in AD, the values were 1.74 ± 0.33, 2.11 ± 0.37 and
2.22 ± 0.13, respectively. (C) C3435T: In HC, BPND values for 0 T, 1 T
and 2 T were 1.73 ± 0.49, 1.73 ± 0.44 and 1.88 ± 0.39, and in AD, the
values were 1.56 ± 0.15, 2.17 ± 0.30 and 2.13 ± 0.27, respectively.
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AD patients, genetic variations in ABCB1 might contri-
bute to the progression of amyloid-beta deposition in
the brain.
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